<li>benazepril<p>losartan, benazepril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li><li>captopril<p>losartan, captopril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li><li>enalapril<p>losartan, enalapril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li><li>fosinopril<p>losartan, fosinopril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li><li>idelalisib<p>idelalisib will increase the level or effect of losartan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates</p></li><li>ivacaftor<p>ivacaftor, losartan.
Either increases levels of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Ivacaftor and its M1 metabolite has the potential to inhibit CYP3A4, may significantly increase systemic exposure to CYP3A4 substrates.</p></li><li>lisinopril<p>losartan, lisinopril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li><li>lithium<p>losartan increases toxicity of lithium by decreasing renal clearance. Avoid or Use Alternate Drug.</p></li><li>moexipril<p>losartan, moexipril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li><li>perindopril<p>losartan, perindopril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li><li>potassium phosphates, iv<p>losartan and potassium phosphates, iv both increase  serum potassium. Avoid or Use Alternate Drug.</p></li><li>quinapril<p>losartan, quinapril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li><li>ramipril<p>losartan, ramipril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li><li>trandolapril<p>losartan, trandolapril.
Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Dual blockade of renin-angiotensin system increases risks of hypotension, hyperkalemia, and renal impairment.</p></li>